Regulation of renin enhancer activity by nuclear factor I and Sp1/Sp3

Pan Li, Sean T. Glenn, Craig A. Jones, Richard M. Gronostajski, Kenneth W. GrossBiochimica 2003 · DOI

TL;DR

This study identifies key transcription factor binding sites within a critical enhancer region of the mouse Renin-1 gene. By dissecting the enhancer's regulatory elements, the researchers pinpoint Nuclear Factor I (NFI) and Sp1/Sp3 as crucial players in controlling renin gene expression, with a particular emphasis on the NFI-X isoform. This work sheds light on the intricate molecular mechanisms governing renin production, a vital hormone in blood pressure regulation.

What Problem Does This Paper Address?

Renin is a crucial enzyme in the renin-angiotensin-aldosterone system (RAAS), which plays a central role in regulating blood pressure and fluid balance. The precise control of renin gene expression is paramount, as dysregulation can lead to hypertension and other cardiovascular diseases. While it's known that renin gene expression is tightly regulated in a tissue- and developmental-specific manner, the detailed molecular mechanisms, particularly the transcription factors involved in activating the renin gene, remain incompletely understood. Previous research had identified a proximal promoter and a distal enhancer region (-2866 to -2625 bp upstream of the transcription start site) as essential for Renin-1 gene expression in kidney tumor-derived As4.1 cells. However, the specific transcription factors binding to this enhancer and their individual contributions to gene regulation were not fully elucidated. This paper aims to identify these factors and understand their roles in controlling Renin-1 expression.

Methods

The researchers employed a combination of molecular biology techniques to dissect the renin enhancer's regulatory elements:

  • Plasmid Construction and Transient Transfection: Various constructs containing different segments of the Renin-1 enhancer fused to a luciferase reporter gene were created. These were then transfected into As4.1 cells to measure their effect on gene expression. Luciferase activity, normalized to B-galactosidase activity, served as a readout for enhancer activity.
  • Electrophoretic Mobility Shift Assay (EMSA): This technique was used to identify specific DNA-protein interactions. Labeled DNA probes corresponding to different regions of the enhancer were incubated with nuclear extracts from As4.1 cells. The formation of shifted bands indicated the binding of transcription factors to the DNA.
  • Competition and Supershift EMSA: To confirm the identity of the binding factors, competition assays were performed using unlabeled DNA fragments. Supershift assays involved adding antibodies against specific transcription factors (like NFI, Sp1, and Sp3) to the reaction mixture to see if the DNA-protein complex shifted further, indicating antibody binding.
  • RNA Isolation and Reverse Transcription-Polymerase Chain Reaction (RT-PCR): Total RNA was isolated from As4.1 cells to study gene expression. RT-PCR was used to detect and quantify the mRNA levels of different Nuclear Factor I (NFI) isoforms.
  • Real-time RT-PCR: This quantitative method was used to precisely measure the expression levels of NFI isoforms, allowing for a comparison of their abundance in As4.1 cells.

Datasets

Not discussed in the paper. The study primarily relies on in vitro experiments using cultured cells and synthesized DNA constructs.

Key Insights and Ideas

  • The distal enhancer is a complex regulatory hub: Beyond previously identified elements like the CRE and E-box, the distal portion of the Renin-1 enhancer (-2866 to -2699 bp) harbors multiple, critical transcription factor binding sites.
  • NFI is a major player: The study definitively identifies four distinct NFI binding sites within the enhancer. Mutations in these sites collectively led to an almost complete loss of enhancer activity, highlighting the indispensable role of NFI family members.
  • Sp1/Sp3 also contribute significantly: A specific Sp1/Sp3 binding site was identified, and its mutation reduced Renin-1 expression by 40%, underscoring its importance.
  • NFI-X is the dominant NFI isoform: In the As4.1 cells, NFI-X mRNA was found to be overwhelmingly predominant compared to other NFI isoforms (NFI-A, -B, and -C). This strongly suggests that NFI-X is the primary NFI factor responsible for regulating Renin-1 expression in these cells.
  • Cooperative action of regulatory elements: While individual mutations of some sites caused moderate decreases in expression, mutations of multiple sites, particularly the NFI binding sites, had a cumulative and dramatic effect, indicating a cooperative mechanism of regulation.
  • Potential for cross-species conservation: The identified enhancer region shows sequence similarity to the human renin gene enhancer, suggesting that some of these regulatory elements and the factors that bind them may be conserved across species.

Key Results

  • Mutations in the four identified NFI binding sites resulted in an 89% decrease in Renin-1 expression.
  • Mutation of the Sp1/Sp3 binding site reduced expression by 40%.
  • Mutation of an unidentified transcription factor binding site (Ei) reduced expression by 30%.
  • The half NFI binding site (Eh) was found to be particularly critical, with its mutation causing a 60% reduction in expression.
  • Mutations in both Eh and Eg resulted in a loss of activity comparable to deleting the entire distal enhancer region.
  • Real-time RT-PCR revealed that NFI-X mRNA was highly abundant in As4.1 cells, while NFI-A, -B, and -C were present at extremely low levels.

Limitations and Future Work

  • Identity of the "Ei" factor: While a binding site (Ei) was identified and its mutation affected expression, the specific transcription factor that binds to this site remains unknown. Further investigation is needed to identify this factor.
  • Antibody specificity: The anti-NFI antibody used in supershift assays was generated against human NFI-C. While it showed supershift activity, its cross-reactivity with NFI-X, the predominant isoform in As4.1 cells, was not definitively confirmed. Future studies could benefit from isoform-specific antibodies.
  • Tissue specificity: This study was conducted in As4.1 kidney tumor cells. While these cells are a valuable model, the findings may not directly translate to all tissues or physiological conditions where renin is expressed. Further studies in primary cells and in vivo models are necessary to confirm the broader relevance of these findings.
  • Direct study of NFI-X: The authors state that direct study of NFI-X's involvement in renin gene regulation is underway, indicating a clear path for future research. This would likely involve experiments using NFI-X knockdown or overexpression to confirm its functional role.
  • Interactions with other regulatory elements: The discussion hints at indirect interactions between distal enhancer factors and proximal promoter elements. Exploring these complex interplay mechanisms would be a valuable next step.

Summary updated

BibTeX
@inproceedings{li2003regulation,
  author = {Pan Li and Sean T. Glenn and Craig A. Jones and Richard M. Gronostajski and Kenneth W. Gross},
  title = {{Regulation of renin enhancer activity by nuclear factor I and Sp1/Sp3}},
  booktitle = {Biochimica},
  year = {2003},
  doi = {10.1016/s0167-4781(03)00016-2},
}
Figure